间充质干细胞及其外泌体在治疗炎症性肠病中的研究进展  

Research progress of mesenchymal stem cells and their exosomes in the treatment of inflammatory bowel disease

作　　者：王顺娜 伍杨 郑晓凤[3] 于晓辉 张久聪 WANG Shunna;WU Yang;ZHENG Xiaofeng;YU Xiaohui;ZHANG Jiucong(Department of Gastroenterology,the 940th Hospital of Joint Logistic Support Force of PLA,Lanzhou 730050;The First Clinical College of Medicine,Gansu University of Traditional Chinese Medicine;Department of Gastroenterology,the Second Hospital of Lanzhou University,China)

机构地区：[1]中国人民解放军联勤保障部队第九四〇医院消化内科,甘肃兰州730050 [2]甘肃中医药大学第一临床医学院 [3]兰州大学第二医院消化内科

出　　处：《胃肠病学和肝病学杂志》2025年第3期443-447,452,共6页Chinese Journal of Gastroenterology and Hepatology

基　　金：中央高校优秀青年团队培育项目(31920220065);甘肃省卫生健康行业科研项目(GSWSKY2023-34);第九四〇医院研究生导师专项课题(2023YXKY020)。

摘　　要：炎症性肠病(inflammatory bowel disease,IBD)是一种慢性炎症性疾病,目前病因尚不明确。间充质干细胞(mesenchymal stem cells,MSCs)及其外泌体(MSCs-exosomes,MSCs-EXO)因其具有免疫调节和促生存的特性,现已成为治疗IBD的一种新兴治疗方式。它们可以通过分泌多种抗炎因子来抑制炎症的发生,促进疾病的缓解。近年来也被广泛应用于临床。但其中许多机制尚不清楚,需要我们进一步探索和研究。因此本文就MSCs及MSCs-EXO在IBD中的作用机制及研究进展作一综述,供临床医师参考。Inflammatory bowel disease(IBD)is a chronic inflammatory disease with an unclear etiology.Mesenchymal stem cells(MSCs)and their exosomes(MSCs-EXO)are now an emerging therapeutic modality for the treatment of IBD due to their immunomodulatory and pro-survival properties.They can inhibit inflammation and promote disease remission by secreting multiple anti-inflammatory factors.They have also been widely used in clinical practice in recent years.However,many of these mechanisms are still unclear and need to be further explored and investigated.Therefore,this article provided a review of the mechanism of action and research progress of MSCs and MSCs-EXO in IBD for clinicians′reference.

关 键 词：间充质干细胞 外泌体 治疗 炎症性肠病 研究进展 

分 类 号：R574.62[医药卫生—消化系统]